Science Daily

CRISPR unlocks a new way to defeat resistant lung cancer

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were ...
Business Wire

CorriXR Therapeutics Announces Publication of Additional Preclinical Data Corroborating Ability of NRF2 Knockout to Restore Chemosensitivity in Solid Tumors

Peer-reviewed results in Molecular Therapy Oncology show that targeted, mutation-agnostic CRISPR gene editing of NRF2 in head and neck cancer models resensitizes treatment resistant tumors to ...
ascopubs.org

High grade serous ovarian cancer differentiation and invasion post chemotherapy: Role of NRF2.

Real world data of maintenance treatment in homologous recombination (HR)–proficient HGSOC. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full ...
ascopubs.org

Chemoresistance in high grade serous ovarian cancer molecular subtypes and the role of NRF2.

Unveiling primary platinum resistant ovarian cancer: Demographic and clinical perspectives from multicenter cancer registry in India. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting ...
BioWorld

NRF2 inhibitors reported in Genfleet Therapeutics patent

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to ...